Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Christine Freedman"'
Autor:
Xiaoling Yang, Keith Flaherty, Jun Guo, Xue Bai, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoting Wei, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Genevieve Boland
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background Although the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-programmed cell death protein 1 (anti-PD-1) therapy, there is lack of real-world data rega
Externí odkaz:
https://doaj.org/article/b9ec8468e1164c759afecff19f29e93a
Autor:
Xiaoling Yang, Keith Flaherty, Jun Guo, Xue Bai, Justine Cohen, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoting Wei, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Genevieve Boland
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/beefe4f12af54d7481d8f66693081c5a
Autor:
Xue Bai, Alexander N. Shoushtari, Allison Betof Warner, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Henry T. Quach, Christopher G. Cann, Michael Z. Zhang, Lalit Pallan, Catriona Harvey, Michelle S. Kim, Gyulnara Kasumova, Tatyana Sharova, Justine V. Cohen, Donald P. Lawrence, Christine Freedman, Riley M. Fadden, Krista M. Rubin, Dennie T. Frederick, Keith T. Flaherty, Georgina V. Long, Alexander M. Menzies, Ryan J. Sullivan, Genevieve M. Boland, Douglas B. Johnson, Jun Guo
Publikováno v:
British Journal of Dermatology. 187:401-410
Background Programmed cell death receptor-1 (PD-1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white populations and remain poorly characterized in other ethnic groups, such as Eas
Autor:
Bixia Tang, Lu Si, Michael Z. Zhang, Xiaoting Wei, Tatyana Sharova, Michael Manos, Gyulnara G. Kasumova, Ryan J. Sullivan, Keith T. Flaherty, Henry T. Quach, Krista M. Rubin, Christine Freedman, Osama E. Rahma, Douglas B. Johnson, Allison Betof Warner, Alexander N. Shoushtari, Xiaoling Yang, Olivia Ouyang, Justine V. Cohen, Xue Bai, Lalit Pallan, Christopher G. Cann, Jun Guo, Donald P. Lawrence, Catriona Harvey, Alexander M. Menzies, Chuanliang Cui, Dennie T. Frederick, Jiani Hu, Georgina V. Long, Michelle S. Kim, Genevieve M. Boland, Riley Fadden
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(21)
Purpose: Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require immunosuppressive treatment with glucocorticoids (GCCs), but GCC use and its correlati
Autor:
Dennie T. Frederick, Chuanliang Cui, Michelle Kim, Xiaoting Wei, Jun Guo, Riley Fadden, Krista M. Rubin, Xiaoling Yang, Christine Freedman, Genevieve M. Boland, Bixia Tang, Donald P. Lawrence, Gyulnara G. Kasumova, Ryan J. Sullivan, Keith T. Flaherty, Justine V. Cohen, Lu Si, Xue Bai, Tatyana Sharova
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background The SITC Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-PD-1 therapy,1 yet there is little data that compares these two scenarios. In particular, detailed radiological dynamics of the different
Autor:
Alexander T. Faje, Justine V. Cohen, Donald P. Lawrence, Krista M. Rubin, Christine Freedman, Ryan J. Sullivan, Riley Fadden, Keith T. Flaherty
Publikováno v:
Cancer. 124:3706-3714
Background It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune-related adverse events (irAEs) and improved survival, this st
Autor:
Tatyana Sharova, Donald P. Lawrence, Genevieve M. Boland, Christine Freedman, Justine V. Cohen, Keith T. Flaherty, Riley Fadden, Michelle S. Kim, Krista M. Rubin, Gyulnara G. Kasumova, Ryan J. Sullivan, Xue Bai
Publikováno v:
Cancer Research. 80:B25-B25
Background: Although immune-related adverse effects (irAEs) are commonly seen in anti-PD-1 monotherapy-treated patients, their predictive biomarkers are still lacking. Methods: In this retrospective analysis, clinical data were collected from 141 adv
Autor:
Genevieve M. Boland, Sarah Richey, Moshe Sade-Feldman, Christine Freedman, Meghan J. Mooradian, Russell W. Jenkins, Steven M. Blum, Donald P. Lawrence, Riley Fadden, Justine V. Cohen, Dennie T. Frederick, Jennifer A. Wargo, Neal Smith, Alexandra C Villani, Keith T. Flaherty, Ryan J. Sullivan, Nir Hacohen, Krista M. Rubin
Publikováno v:
Journal of Clinical Oncology. 38:3116-3116
3116 Background: The mechanistic relationship between clinical benefit and immune-related adverse events (irAEs) in response to immune checkpoint inhibitors (ICIs) remains unclear, with several clinical studies reporting that irAEs are biomarkers of
Autor:
Tatyana Sharova, Justine V. Cohen, Krista M. Rubin, Dennie T. Frederick, Donald P. Lawrence, Christine Freedman, Michelle S. Kim, Genevieve M. Boland, Riley Fadden, Gyulnara G. Kasumova, Ryan J. Sullivan, Xue Bai, Keith T. Flaherty
Publikováno v:
Journal of Clinical Oncology. 37:9552-9552
9552 Background: Melanoma is notorious for its high degree of heterogeneity with the implication that metastases in different sites react differently to immunotherapy. We aimed to explore the site-specific response pattern in anti-PD-1 monotherapy tr
Autor:
Gyulnara G. Kasumova, Ryan J. Sullivan, Genevieve M. Boland, Keith T. Flaherty, Xue Bai, Justine V. Cohen, Krista M. Rubin, Christine Freedman, Donald P. Lawrence, Riley Fadden, Michelle S. Kim, Tatyana Sharova
Publikováno v:
Journal of Clinical Oncology. 37:133-133
133 Background: Anti-PD-1 monotherapy has dramatically improved the outcomes of patients with advanced melanoma, yet the majority of patients develop therapeutic resistance. A prognostic model is needed to optimally select patients who are most and l